Latest Conference Coverage


Laura Sebrow, PhD  (Credit: LinkedIn)

Exploring Cognitive Difficulties in Migraine: Aligning Subjective and Objective Findings

June 22nd 2025

Laura Sebrow, PhD, a post doctoral neuropsychology fellow at North Shore University Hospital, discussed the relationship between patients’ reported cognitive difficulties and measurable cognitive performance during different migraine phases.


 Marcela Romero-Reyes, DDS, PhD, FAHS  (Credit: LinkedIn)

Targeting A3AR in Trigeminal Neuropathic Pain: A Promising Approach for an Unmet Clinical Need

June 21st 2025

Marcela Romero-Reyes, DDS, PhD, FAHS, director of the Brotman Facial Pain Clinic at the University of Maryland, discussed a promising and potentially safer therapeutic approach for managing trigeminal neuropathic pain.


The Overlooked Role of Obstructive Sleep Apnea in Alzheimer Pathogenesis

The Overlooked Role of Obstructive Sleep Apnea in Alzheimer Pathogenesis

June 20th 2025

Omonigho Michael Bubu, MD, PhD, an associate professor of psychiatry, neurology, & population health at NYU Langone, discussed how OSA contributes to Alzheimer disease risk through race- and sex-specific mechanisms and neurodegenerative biomarkers.


Post Hoc Analyses Shed Light on Safety and Efficacy of Once-Nightly Sodium Oxybate in Narcolepsy Care

Post Hoc Analyses Shed Light on Safety and Efficacy of Once-Nightly Sodium Oxybate in Narcolepsy Care

June 19th 2025

Richard Bogan, MD, FCCP, FAASM, an associate clinical professor at the University of South Carolina School of Medicine, discussed a bevy of presentations from the 2025 SLEEP Annual Meeting highlighting the effects of once-nightly sodium oxybate.


Overviewing SLEEP 2025: Thoughts and Perspectives From the President of AASM

Overviewing SLEEP 2025: Thoughts and Perspectives From the President of AASM

June 19th 2025

Anita Shelgikar, MD, a clinical professor at the University of Michigan and president of the American Academy of Sleep Medicine, provided post-conference perspectives on the 2025 SLEEP meeting, giving clinicians insights on the latest in research and treatment updates.


Centessa to Advance Orexin Agonist ORX142 to Clinical Trials Following IND Acceptance

Centessa to Advance Orexin Agonist ORX142 to Clinical Trials Following IND Acceptance

June 18th 2025

Centessa Pharmaceuticals initiates Phase 1 study for ORX142, a novel orexin receptor agonist targeting neurological disorders, promising new treatment avenues.


Cassandra Moore, MPH, CPH

Exploring the Clinical Impact of Health and Wellness Coaching in MS Care: Cassandra Moore, MPH, CPH

June 18th 2025

The associate vice president of strategy and innovation at the National MS Society highlighted the measurable benefits of health and wellness coaching for individuals with multiple sclerosis. [WATCH TIME: 5 minutes]


NeuroVoices: Tiffany Malone, MSW, MSCS, on Combating Loneliness in MS Care Through Connection and Community Programs

NeuroVoices: Tiffany Malone, MSW, MSCS, on Combating Loneliness in MS Care Through Connection and Community Programs

June 18th 2025

The director of the John A. Schafer, MD Multiple Sclerosis Achievement Center at Dignity Health discussed the effect of loneliness and social isolation on individuals living with multiple sclerosis.


Sam Hooshmand, DO

Challenges and Considerations in the Care Management of Advanced Stages of Multiple Sclerosis: Sam Hooshmand, DO

June 17th 2025

The assistant professor of neurology at the Medical College of Wisconsin talked about the complexities of advanced multiple sclerosis, highlighting gaps in clinical trials and the need for individualized care strategies. [WATCH TIME: 3 minutes]


Bridging Sleep Science and Biomarkers in Neurodegeneration: Lea Grinberg, MD, PhD

Bridging Sleep Science and Biomarkers in Neurodegeneration: Lea Grinberg, MD, PhD

June 17th 2025

The neuropathologist at Mayo Clinic Florida discussed why EEG-based sleep biomarkers may help detect Alzheimer disease earlier and how they could enhance clinical trial design. [WATCH TIME: 3 minutes]


Funke Afolabi-Brown, MD, FAASM

Using a Family-Centered Approach for Care in Pediatric Sleep Health: Funke Afolabi-Brown, MD, FAASM

June 17th 2025

The chief executive officer of Restful Sleep MD emphasized the importance of tailoring pediatric sleep interventions to each family’s unique structure, values, and challenges. [WATCH TIME: 5 minutes]


Emerging Pharmacotherapies Offer New Hope in Obstructive Sleep Apnea Treatment

Emerging Pharmacotherapies Offer New Hope in Obstructive Sleep Apnea Treatment

June 16th 2025

The director of sleep health at Flinders University discussed the latest clinical advances in pharmacotherapy, precision treatment targets, and combination strategies for obstructive sleep apnea.


Deepa Burman, MD, FAASM  (Credit: UPMC)

Understanding Pediatric Insomnia: Risk Factors, Clinical Diagnosis, and Care Management

June 16th 2025

Deepa Burman, MD, FAASM, co-director of the Pediatric Sleep Evaluation Center at UPMC Children’s Hospital of Pittsburgh, discussed the potential contributors to pediatric insomnia and the role of a thorough assessment for effective management.


Funke Afolabi-Brown, MD, FAASM  (Credit: Restful Sleep MD)

Looking at the Importance of Family-Centered Care Approaches in Pediatric Sleep Medicine

June 13th 2025

Funke Afolabi-Brown, MD, FAASM, chief executive officer of Restful Sleep MD, discussed the potential role of family dynamics and individualized planning in the effective management of pediatric sleep disorders.


Kevin Swong, MD

Emerging Considerations in Peripheral Nerve Injury and Surgical Intervention: Kevin Swong, MD

June 12th 2025

The neurosurgeon at Northwestern Medicine discussed diagnostic approaches, evolving treatment strategies, and the importance of timely referral in managing peripheral nerve injuries. [WATCH TIME: 3 minutes]


Phase 2 Study to Test Therapeutic Potential of Samelisant for Narcolepsy Type 1

Phase 2 Study to Test Therapeutic Potential of Samelisant for Narcolepsy Type 1

June 12th 2025

A new phase 2 study explores samelisant's potential to treat cataplexy in narcolepsy type 1, promising improved patient outcomes and safety.


National RLS Registry Provides Long-Term Insights Into Opioid Use for Restless Legs Syndrome

National RLS Registry Provides Long-Term Insights Into Opioid Use for Restless Legs Syndrome

June 12th 2025

New 5-year findings from the National RLS Opioid Registry presented at SLEEP 2025 highlight the long-term stability and dose trends of low-dose opioid therapy in patients with restless legs syndrome.


Rationale Behind NVG-2089 as New Therapy for CIDP: Pamela Conley; Alan Glicklich, MD

Rationale Behind NVG-2089 as New Therapy for CIDP: Pamela Conley; Alan Glicklich, MD

June 12th 2025

Members from Nuvig Therapeutics discussed how NVG-2089 could improve the CIDP treatment landscape by offering IVIG-like efficacy with a better safety and administration profile. [WATCH TIME: 3 minutes]


Small-Scale Study Highlights Positive Impacts of Once-Nightly Sodium Oxybate on Sleep-Related Eating Disorder

Small-Scale Study Highlights Positive Impacts of Once-Nightly Sodium Oxybate on Sleep-Related Eating Disorder

June 11th 2025

Switching to once-nightly sodium oxybate significantly improves sleep-related eating disorder in narcolepsy patients, enhancing overall treatment outcomes.


Elias Karroum, MD, PhD  (Credit: University of Virginia School of Medicine)

Tonic Motor Activation Effective in Treating Both Painful and Painless Restless Legs Syndrome

June 11th 2025

An interim analysis of an ongoing study suggested that the tonic motor activation demonstrated comparable short-term outcomes for both painful and painless forms of restless legs syndrome.


Supporting Stroke Recovery Through the Glymphatic System: Joyce Lee-Iannotti, MD, FAAN, FAASM

Supporting Stroke Recovery Through the Glymphatic System: Joyce Lee-Iannotti, MD, FAAN, FAASM

June 11th 2025

The sleep and stroke neurologist at Barrow Neurological Institute detailed how improving glymphatic function may prevent strokes and enhance recovery from both hemorrhagic and ischemic events. [WATCH TIME: 5 minutes]


Logan Schneider, MD  (Credit: Stanford University)

Low-Sodium Oxybate Improves Daytime Sleepiness and Sleep Architecture in Phase 4 Narcolepsy Trial

June 11th 2025

Findings from the Jazz DUET study presented at SLEEP 2025 showed that low-sodium oxybate reduced daytime sleepiness and improved sleep parameters in patients with narcolepsy types 1 and 2.


Exploring the Overlooked Role of Orexin in Alzheimer Disease and Sleep Dysfunction: Lea Grinberg, MD, PhD

Exploring the Overlooked Role of Orexin in Alzheimer Disease and Sleep Dysfunction: Lea Grinberg, MD, PhD

June 11th 2025

The neuropathologist at Mayo Clinic Florida discussed her presentation from SLEEP 2025, outlining how early tau accumulation in wake-promoting brain regions contributes to sleep disturbances before Alzheimer disease symptoms arise. [WATCH TIME: 3 minutes]


NeuroVoices: Andrew Varga, MD, on Debating Whether Brain Cleansing Prevents Alzheimer Disease

NeuroVoices: Andrew Varga, MD, on Debating Whether Brain Cleansing Prevents Alzheimer Disease

June 11th 2025

The neuroscientist and physician at Mount Sinai explored the role of sleep-dependent brain clearance in Alzheimer disease and how emerging research is challenging longstanding assumptions.


Terri E. Weaver, PhD, RN, FAAN, ATSF, FAASM  (Credit: University of Illinois Chicago)

Post-Hoc Analysis Links Tirzepatide Treatment to Reduced Daytime Sleepiness in OSA and Obesity

June 10th 2025

Data from a pair of phase 3 trials suggest that tirzepatide treatment may improve patient-reported measures of sleepiness in individuals with obstructive sleep apnea and obesity.


Adapting Cognitive Behavioral Therapy for Nightmare Disorder in Children: Lisa Cromer, PhD

Adapting Cognitive Behavioral Therapy for Nightmare Disorder in Children: Lisa Cromer, PhD

June 10th 2025

The professor of psychology at the University of Tulsa provided insight on how her team adapted CBT for children with nightmares using a learning-theory approach that targets the fear-avoidance cycle. [WATCH TIME: 5 minutes]


Yishu Gong, PhD, MPH  (Credit: LinkedIn)

Investigational Therapy TAK-861 Reduces Microsleeps in Phase 2 Trial of Narcolepsy Type 1

June 10th 2025

New phase 2 trial data presented at SLEEP 2025 suggest TAK-861 significantly decreased microsleep frequency and delayed onset of first microsleep in individuals with narcolepsy type 1.

© 2025 MJH Life Sciences

All rights reserved.